39270-39-8

Basic information

• Product Name: 2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHANOL
• Synonyms: RARECHEM AL BD 0202;3,4-ETHYLENEDIOXYBENZYL ALCOHOL;2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHANOL;2,3-dihydro-1,4-benzodioxin-6-methanol;6-(Hydroxymethyl)-2,3-dihydro-1,4-benzodioxin;(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanol;2,3-Dihydro-6-(hydroxymethyl)-1,4-benzodioxine;(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-Methanol
• CAS NO: 39270-39-8
• Molecular Formula: C₉H₁₀O₃
• Molecular Weight: 166.17
• EINECS: 254-396-7
• Product Categories: Benzhydrols, Benzyl & Special Alcohols
• Mol File: 39270-39-8.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 129 °C
• Flash Point: 135.98 °C
• Appearance: /
• Density: 1.257g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.25±0.10(Predicted)
• CAS DataBase Reference: 2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHANOL(39270-39-8)
• EPA Substance Registry System: 2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHANOL(39270-39-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-51-41-37/38
• Safety Statements: 26-36/37/39-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 39270-39-8(Hazardous Substances Data)

Usage

General Description

2,3-Dihydro-1,4-benzodioxin-6-ylmethanol is a chemical compound that is derived from the organic compound benzodioxin. It is an aromatic alcohol with a molecular structure containing two benzene rings fused to a 1,4-dioxin ring. 2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHANOL is used in the pharmaceutical and chemical industries as a building block for the synthesis of various drugs and other organic compounds. It is also known for its potential biological activity and is studied for its potential applications in medicine. Additionally, this chemical has the potential for use in organic synthesis and chemical research due to its unique structure and properties.

InChI:InChI=1/C9H10O3/c10-6-7-1-2-8-9(5-7)12-4-3-11-8/h1-2,5,10H,3-4,6H2

Upstream product

• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 20825-87-0 2,3-dihydrobenzo[1,4]dioxine-6-carboxylic acid ethyl ester 
• 3943-89-3 Ethyl protocatechuate 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 

Downstream Products

• 26309-99-9 6-(chloromethyl)-2,3-dihydrobenzo[b][1,4]dioxine 
• 79440-34-9 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 940365-60-6 C₁₅H₁₅NO₂ 
• 1228189-80-7 [(S)-1-(5-benzyl-7-cyano-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-6-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester 
• 103175-32-2 3-Benzoyl-1-[1-(1,4-benzodioxan-6-ylmethyl)piperid-4-yl]-urea 

Relevant articles and documents

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents

1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-substituted-phenylpiperazine moiety was prepared and has been found to be a new and selective ligand for the enzyme cyclooxygenase-2 (COX-2). The biological activity of compound 3k as anti-inflammatory agent was further investigated both in vitro and in vivo. Notably, compound 3k exhibited the best anti-inflammatory activity among the eleven designed compounds with no toxicity, as determined by the ulcerogenic activity. Computational docking studies also showed that compound 3k has interaction with COX-2 key residues in the active site. Compound 3k maybe a new anti-inflammatory lead-candidate as powerful and novel non-ulcerogenic.

Synthesis, in vitro antimycobacterial and antibacterial evaluation of IMB-070593 derivatives containing a substituted benzyloxime moiety

A series of novel IMB-070593 derivatives containing a substituted benzyloxime moiety and displaying a remarkable improvement in lipophilicity were synthesized and evaluated for their in vitro antimycobacterial and antibacterial activity. Our results reveal that the target compounds 19a-m have considerable Gram-positive activity (MIC: 0.008-32 μg/mL), although they are generally less active than the reference drugs against the Gram-negative strains. In particular, compounds 19h, 19j, 19k and 19m show good activity (MICs: 0.008-4 μg/mL) against all of the tested Gram-positive strains, including ciprofloxacin (CPFX)- and/or levofloxacin (LVFX)-resistant MSSA, MRSA and MSSE. Moreover, compound 19l (MIC: 0.125 μg/mL) is found to be 2-4 fold more active than the parent IMB070593, CPFX and LVFX against M. tuberculosis H37Rv ATCC 27294.